Ischemic modified albumin increases in acute kidney injury

Open access


Purpose: Acute kidney injury (AKI) is a severe kidney disease carrying high morbidity and mortality. An ischemic process, at the cellular level, has been detected prior to the full-blown AKI. An elevated ischemic modified albumin (IMA) was also found to be increased fast at several minutes following an ischemic process in the body. In this connection, we have investigated, in advance, the changes of IMA concentrations in patients with possible AKI. Methods: IMA and other biochemical and haematological parameters were measured in sera of thirty nine patients with AKI and of thirty eight healthy controls. AKI is defined by an increase in serum creatinine by ≥ 0.3 mg/dl in 48 hours or an increase by ≥ 1.5-fold from a known or assumed baseline. The results in the two groups were compared. Results: IMA, creatinine, blood urea nitrogen, white blood cell, neutrophil, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and mean platelet volume were found to be higher in patients with AKI than in healthy controls. In contrast, total protein, albumin, lymphocyte, and haemoglobin were lower in patients with AKI than in healthy controls. No significant difference was recorded in platelet counts between the two groups. Conclusion: Our results indicate that increased levels of NLR and PLR play a central role in a systemic inflammation in AKI. Monitoring serum IMA could be a useful tool in the assessment of AKI.

1. Chawla LS, Amdur RL, Shaw AD, Faselis C, Palant CE, Kimmel PL. Association between AKI and longterm renal and cardiovascular outcomes in united states veterans. Clin J Am Soc Nephrol. 2014;9(3):448-56. DOI: 10.2215/CJN.02440213

2. Bellomo R, Auriemma S, Fabbri A, D’Onofrio A, Katz N, McCullough PA, et al. The pathophysiology of cardiac surgery-associated acute kidney injury (CSAAKI). Vol. 31, International Journal of Artificial Organs. 2008. p. 166-78.

3. Nangaku M, Rosenberger C, Heyman SN, Eckardt KU. Regulation of hypoxia-inducible factor in kidney disease. Clin Exp Pharmacol Physiol. 2013;40(2):148-57. DOI: 10.1111/1440-1681.12005

4. Yousefipour Z, Oyekan A, Newaz M. Interaction of oxidative stress, nitric oxide and peroxisome proliferator activated receptor gamma in acute renal failure. Pharmacol Ther. 2010;125(3):436-45. DOI: 10.1016/j. pharmthera.2009.12.004

5. Verma P, Bhattacharya SN, Banerjee BD, Khanna N. Oxidative stress and leukocyte migration inhibition response in cutaneous adverse drug reactions. Indian J Dermatol Venereol Leprol. 2012;78(5):664. DOI: 10.4103/0378-6323.100519

6. Devarajan P. Neutrophil gelatinase-associated lipocalin - An emerging troponin for kidney injury. Vol. 23, Nephrology Dialysis Transplantation. 2008. p. 3737-43. DOI: 10.1093/ndt/gfn531

7. Gaut JP, Crimmins DL, Ohlendorf MF, Lockwood CM, Griest TA, Brada NA, et al. Development of an immunoassay for the kidney-specific protein myo-inositol oxygenase, a potential biomarker of acute kidney injury. Clin Chem. 2014;60(5):747-57. DOI: 10.1373/clinchem.2013.212993

8. Petrica L, Gluhovschi A, Gluhovschi C, Gadalean F, Balgradean C, Groza C, et al. Proximal tubule dysfunction in renal diseases - diagnostic significance of proteomics and biomarkers. Rev Romana Med Lab. 2012;20(2):97-107.

9. Şalaru DL, Macovei L, Stătescu C, Arsenescu-Georgescu C. Assessement of microalbuminuria in hypertensive patients with established coronary artery disease. Rev Romana Med Lab. 2013;21(4):407-14. DOI: 10.2478/rrlm-2013-0041

10. Haase-Fielitz A, Bellomo R, Devarajan P, Story D, Matalanis G, Dragun D, et al. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery--a prospective cohort study. Crit Care Med. 2009;37(2):553-60. DOI: 10.1097/CCM.0b013e318195846e

11. Leslie JA, Meldrum KK. The Role of Interleukin-18 in Renal Injury. J Surg Res. 2008;145(1):170-5. DOI: 10.1016/j.jss.2007.03.037

12. Schrezenmeier E V, Barasch J, Budde K, Westhoff T, Schmidt-Ott KM. Biomarkers in acute kidney injury - pathophysiological basis and clinical performance. Acta Physiol (Oxf). 2016; Disponible:

13. Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med. 2010;4(2):265-80. DOI: 10.2217/bmm.10.12

14. Ellidag HY, Eren E, Yilmaz N, Bayindir A. Ischemia Modified Albumin Levels and Increased Oxidative Stress in Patients With Multiple Myeloma / Nivoi Albumina Modifikovanog Ishemijom I Povi[Eni Oksidantni Stres Kod Pacijenata Sa Multiplim Mijelomom. J Med Biochem. 2013;33(2):175-80. DOI: 10.2478/jomb-2013-0027

15. Pantazopoulos I, Papadimitriou L, Dontas I, Demestiha T, Iakovidou N, Xanthos T. Ischaemia modified albumin in the diagnosis of acute coronary syndromes. Vol. 80, Resuscitation. 2009. p. 306-10. DOI: 10.1016/j.resuscitation. 2008.10.035

16. Sharma R, Gaze DC, Pellerin D, Mehta RL, Gregson H, Streather CP, et al. Evaluation of ischaemia-modified albumin as a marker of myocardial ischaemia in endstage renal disease. Clin Sci (Lond). 2007;113(1):25-32. DOI: 10.1042/CS20070015

17. Dursun A, Okumus N, Zenciroglu A. Ischemia- modified albumin (IMA): could it be useful to predict perinatal asphyxia? J Matern Fetal Neonatal Med. 2012;25(11):2401-5. DOI: 10.3109/14767058.2012.697943

18. Kotani K, Kimura S, Gugliucci A. Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease. J Physiol Biochem. 2011;67(3):437-41. DOI: 10.1007/s13105-011-0092-4

19. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - Review and clinical implications. Clin Chem Lab Med. 2011;49(2):177-84. DOI: 10.1515/CCLM.2011.037

20. Shen XL, Lin CJ, Han LL, Lin L, Pan L, Pu XD. Assessment of ischemia-modified albumin levels for emergency room diagnosis of acute coronary syndrome. Int J Cardiol. Elsevier Ireland Ltd; 2011;149(3):296-8.

21. Yilmaz H, Cakmak M, Inan O, Darcin T, Akcay A. Can neutrophil-lymphocyte ratio be independent risk factor for predicting acute kidney injury in patients with severe sepsis? Ren Fail. 2015;37(2):225-9. DOI: 10.3109/0886022X.2014.982477

22. Velibey Y, Oz A, Tanik O, Guvenc TS, Kalenderoglu K, Gumusdag A, et al. Platelet-to-Lymphocyte Ratio Predicts Contrast-Induced Acute Kidney Injury in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Angiology. 2017 May;68(5):419-27. DOI: 10.1177/0003319716660244

23. Han JS, Park KS, Lee MJ, Kim CH, Koo HM, Doh FM, et al. Mean platelet volume is a prognostic factor in patients with acute kidney injury requiring continuous renal replacement therapy. J Crit Care; 2014;29(6):1016-21. DOI: 10.1016/j.jcrc.2014.07.022

24. Kellum J a, Lameire N, Aspelin P, Barsoum RS, Burdmann E, Goldstein SL, et al. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2(1):1-138.

25. Andringa KK, Agarwal A. Role of hypoxia-inducible factors in acute kidney injury. Nephron - Clin Pract. 2014;127(1-4):70-4. DOI: 10.1159/000363669

26. Kiyici A, Mehmetoglu I, Karaoglan H, Atalay H, Solak Y, Türk S. Ischemia-modified albumin levels in patients with end-stage renal disease patients on hemodialysis: does albumin analysis method affect albumin-adjusted ischemia-modified albumin levels? J Clin Lab Anal. 2010;24(4):273-7. DOI: 10.1002/jcla.20399

27. Kurtul A, Yarlioglues M, Duran M, Murat SN. Association of Neutrophil-to-lymphocyte Ratio with Contrast- induced Nephropathy in Patients with Non-ST-elevation Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention. Hear Lung Circ. 2016;25(7):683-90. DOI: 10.1016/j.hlc.2016.01.007

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information

IMPACT FACTOR 2017: 0.400
5-year IMPACT FACTOR: 0.320

CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2017: 0.144
Source Normalized Impact per Paper (SNIP) 2017: 0.195


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 245 245 20
PDF Downloads 117 117 8